Sep 10, 2012, 10.56 AM | Source: Moneycontrol.com
Shares of Cipla, a drug producer, touched a fresh 52-week high of Rs 395.45 on Monday and rose for the second consecutive session after the company won patent case against Roche.
Roche had filed suit against Cipla on drug Tarceva in 2008. Delhi HC said Cipla’s product Erlocip could be marketed.
At 10:49 hours IST, the share was trading at Rs 392.00, up 0.32% with volumes of 93,700 equity shares.
On Saturday, the share jumped 2.65% to close at Rs 390.75. Market capitalisation of the company currently stands at Rs 31,474.52 crore.
Vittal, a former partner with McKinsey & Company,
Ashwani Gujral of ashwanigujral.com advises buying
Cipla said its UK subsidiary has sold entire stake
Khambatta Securities is bullish on Cipla has recom
CEOs of leading pharma companies will meet to disc